Dr. David Chiswell Ph.D. serves as Independent Chairman of the Board of the Company. He has served as the Chairman of Albireo Limited's board of directors since February 2008. In 1990, Dr. Chiswell co-founded Cambridge Antibody Technology (CAT), an early innovator in the development of antibody drugs, where he was responsible for operational management from 1990 to 2002 and was Chief Executive Officer from 1996 to 2002. For his contributions to the British biotech community, Dr. Chiswell was awarded the Order of the British Empire in 2006. Dr. Chiswell earned his Ph.D. in Virology from the University of Glasgow and his B.Sc. in Microbiology from the Queen Mary College University of London. Since 2002, Dr. Chiswell has focused on the development of early stage biotechnology companies, including serving as Chief Executive Officer of Nabriva Therapeutics AG, now a publicly traded biotechnology company, from April 2009 to May 2012, and as a member of its board of directors from 2006 until August 2016. Dr. Chiswell also served as the Chief Executive Officer of Kymab Ltd., a UK-based therapeutic antibody company, from February 2015 to December 2018. Dr. Chiswell was appointed as a Non-Executive Director of Avillion LLP, a drug development company, in March 2019, and as a Non-Executive Chairman of IGEM Therapeutics Ltd., an immuno-oncology company, in April 2019.
As the Independent Chairman of the Board of Albireo Pharma Inc, the total compensation of David Chiswell at Albireo Pharma Inc is $193,065. There are 8 executives at Albireo Pharma Inc getting paid more, with Ronald Cooper having the highest compensation of $2,995,410.
David Chiswell is 66, he's been the Independent Chairman of the Board of Albireo Pharma Inc since 2016. There are 4 older and 16 younger executives at Albireo Pharma Inc. The oldest executive at Albireo Pharma Inc is Davey Scoon, 73, who is the Independent Director.
David's mailing address filed with the SEC is C/O ALBIREO PHARMA, INC., 53 STATE STREET, 19TH FLOOR, BOSTON, MA, 02109.
Over the last 8 years, insiders at Albireo Pharma Inc have traded over $26,339,822 worth of Albireo Pharma Inc stock and bought 932,623 units worth $30,497,757 . The most active insiders traders include Advisors Llcperceptive Life..., Roger Jeffs und Plcastrazeneca Ab Astrazeneca. On average, Albireo Pharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $957,260. The most recent stock trade was executed by Pamela Stephenson on 23 January 2023, trading 102 units of ALBO stock currently worth $4,468.
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Albireo Pharma Inc executives and other stock owners filed with the SEC include: